You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

Article metrics

Article menu

Download PDFPDF

Regular Abstracts – Part 2
Clinical Trial Completed
629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

 

Online download statistics by month:

Online download statistics by month: October 2023 to June 2025

AbstractFullPdf
Oct 2023400
Nov 2023166018
Dec 20237706
Jan 20242000
Feb 20242402
Mar 20243404
Apr 20242606
May 2024400
Jun 20241200
Jul 20241203
Aug 20241206
Sep 20241401
Oct 20241403
Nov 20242400
Dec 20241403
Jan 20251208
Feb 2025800
Mar 2025001
Apr 2025005
May 2025001
Jun 2025002
Total477069